Plasma cell leukemia (PCL) is the most aggressive form of plasma cell cancer. It is diagnosed when abnormal plasma cells, which normally stay inside the bone marrow, spill into the bloodstream in significant numbers. Current management strategies aim to control it quickly with intensive combination therapy, usually a proteasome inhibitor, an immunomodulatory drug and dexamethasone, often with an anti-CD38 antibody, followed by stem cell transplant and ongoing maintenance in patients fit enough to receive it.
PCL is rare, and many patients and families hear the name for the first time on the day of diagnosis. This guide explains what it is, how it differs from multiple myeloma, how it is diagnosed and how it is treated today.
What Is Plasma Cell Leukemia?
Plasma cells are mature white blood cells that make antibodies. In multiple myeloma, a single abnormal clone of plasma cells multiplies in the bone marrow, crowding out healthy blood production and damaging bone. In PCL, the same kind of malignant plasma cells no longer depend on the marrow and circulate freely in the blood, where they can seed the liver, spleen and other organs.
PCL sits within the wider group of hematologic cancers and comes in two forms:
- Primary PCL: appears from the outset, with no previous myeloma diagnosis.
- Secondary PCL: develops as a late transformation in someone already treated for multiple myeloma. It generally carries a poorer outlook because the disease has already become resistant to several treatments.
How PCL Is Defined Today
For decades, PCL was diagnosed when circulating plasma cells made up at least 20% of white cells, or exceeded an absolute count of 2 × 10^9/L. The International Myeloma Working Group (IMWG) has since lowered the threshold to 5% or more circulating plasma cells in the blood of a patient with myeloma, because patients at that level behave just as aggressively as those above 20%.
| Feature | Multiple myeloma | Plasma cell leukemia |
|---|---|---|
| Circulating plasma cells | Few or none | 5% or more of blood white cells |
| Onset | Often gradual | Typically rapid and severe |
| Organ spread outside marrow | Less common | Liver, spleen, lymph nodes, fluid around the lungs |
| Kidney injury, high calcium, high LDH | Can occur | More frequent and more severe |
| CD56 on plasma cells | Usually present | Often absent |
| Outlook | Varies widely | Poorer, especially for secondary PCL |
Causes and Risk Factors
The exact cause of PCL is unknown. What we do know is that the malignant cells carry genetic changes that let them survive without the marrow’s support. Common findings include translocations involving chromosome 14 (such as t(11;14) and t(14;16)), loss of part of chromosome 13 or chromosome 17 (del(17p)), and gain of 1q. Several of these are recognized high-risk features in myeloma generally.
Broad risk factors for plasma cell cancers include older age, male sex and a history of a precursor condition called monoclonal gammopathy of undetermined significance (MGUS). Radiation and some chemical exposures have been linked to myeloma, but most people with PCL have no identifiable trigger.
Signs and Symptoms
Symptoms overlap with myeloma but tend to arrive faster and be more severe.
- Anemia: fatigue, breathlessness and pallor as the cancer crowds out the red blood cells that carry oxygen.
- Low platelets: easy bruising or bleeding.
- Infections: because normal antibody production is suppressed.
- Hypercalcemia: thirst, confusion, constipation and nausea from high blood calcium.
- Kidney failure: from light-chain damage, high calcium or dehydration.
- Hepatosplenomegaly and lymphadenopathy: an enlarged liver, spleen or lymph nodes.
- Bone pain: although lytic bone lesions are often less prominent than in classic myeloma.
Diagnosis
PCL is often first suspected when a routine blood film shows plasma cells in the circulation. Confirmation and staging involve several tests:
- Peripheral blood smear to count circulating plasma cells.
- Flow cytometry (immunophenotyping) to prove the cells are clonal plasma cells expressing markers such as CD38 and CD138.
- Bone marrow aspirate and biopsy to measure marrow involvement.
- Cytogenetics and FISH to identify chromosomal changes that guide prognosis and treatment.
- Serum and urine protein studies, including free light chains, to measure the abnormal antibody.
- Kidney function, calcium, LDH and beta-2 microglobulin blood tests.
- Imaging, such as whole-body low-dose CT, PET-CT or MRI, to look for bone disease and spread outside the marrow.
Current Management Strategies
Because PCL progresses quickly, treatment starts promptly, and complications such as kidney injury and high calcium are managed alongside anti-cancer therapy.
Induction therapy
The first phase uses combinations proven in high-risk myeloma: a proteasome inhibitor such as bortezomib or carfilzomib, an immunomodulatory drug such as lenalidomide, and dexamethasone. An anti-CD38 monoclonal antibody such as daratumumab is frequently added. In selected cases, conventional chemotherapy is combined in to gain faster control.
Stem cell transplant
For eligible patients, high-dose melphalan followed by autologous stem cell transplantation (using the patient’s own stem cells) is a standard step. Some centers use a second (tandem) transplant, and allogeneic transplant from a donor is considered for carefully selected younger patients, ideally within a clinical trial.
Maintenance and relapse
After transplant, continuous maintenance, often with a lenalidomide- or proteasome inhibitor-based regimen, helps delay relapse. Patients whose cells carry t(11;14) may benefit from venetoclax in some settings. Newer immunotherapies used in myeloma, including CAR T-cell therapy and bispecific antibodies, are being explored in PCL, though patients with PCL have often been excluded from the trials that led to their approval, so evidence remains limited.
Supportive care
Supportive treatment is essential: hydration and medicines for high calcium, bone-protecting drugs, infection prevention, blood transfusions and careful management of kidney function. Enrolling in a clinical trial is encouraged wherever one is available.
When to See a Doctor
Anyone with myeloma should report new or rapidly worsening fatigue, fevers, bruising, confusion, extreme thirst or reduced urine output right away, as these can signal progression. For people without a known diagnosis, unexplained bone pain combined with anemia, recurrent infections or kidney problems deserves prompt blood testing.
Frequently Asked Questions
Is plasma cell leukemia the same as multiple myeloma?
They are closely related cancers of the same cell type. PCL is considered the most aggressive end of the myeloma spectrum, defined by large numbers of malignant plasma cells circulating in the blood.
Can plasma cell leukemia be cured?
PCL is not generally considered curable, but modern combination treatment and transplant can bring deep remissions. Outcomes have improved with newer drugs, particularly for primary PCL treated intensively from the start.
Why is secondary PCL harder to treat?
Secondary PCL arises after myeloma has already been exposed to several treatments, so the cancer cells are often resistant to many drugs. The patient may also be less fit after previous therapy, which limits options such as transplant.
Is plasma cell leukemia hereditary?
No. The genetic changes in PCL are acquired in the cancer cells during life and are not passed on to children.
Key Takeaways
- PCL is a rare, aggressive plasma cell cancer with 5% or more malignant plasma cells in the blood.
- Primary PCL appears de novo; secondary PCL evolves from existing myeloma and has a poorer outlook.
- Diagnosis combines a blood film, flow cytometry, marrow biopsy, cytogenetics and imaging.
- Treatment uses intensive myeloma-style induction, autologous transplant and maintenance.
- Newer immunotherapies are promising but still being studied specifically in PCL.
